Physician’s Orders
BELIMUMAB (BENLYSTA),
SUBCUTANEOUS -
ADULT, OUTPATIENT,
INFUSION CENTER
Page 1 to 1

Defaults for orders not otherwise specified below:
☐ Interval: Every 7 days

Duration:
☐ Until date: __________
☐ 1 year
☐ _______ # of Treatments

Anticipated Infusion Date_____________ ICD 10 Code with Description__________________________________

Height_________________ (cm) Weight______________ (kg) Allergies______________________________________

Provider Specialty
☐ Allergy/Immunology ☐ Infectious Disease ☐ OB/GYN ☐ Rheumatology
☐ Cardiology ☐ Internal Med/Family Practice ☐ Other ☐ Surgery
☐ Gastroenterology ☐ Nephrology ☐ Otolaryngology ☐ Urology
☐ Genetics ☐ Neurology ☐ Pulmonary ☐ Wound Care

Site of Service
☐ SH Gerber ☐ SH Lemmen Holton (GR) ☐ SH Pennock ☐ SH United Memorial
☐ SH Helen DeVos (GR) ☐ SH Ludington ☐ SH Reed City ☐ SH Zeeland

Appointment Requests
☐ Infusion Appointment Request
Status: Future, Expected: S, Expires: S+365, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after, Injection

Nursing Orders
☐ ONC NURSING COMMUNICATION 14
BELIMUMAB (BENLYSTA):
An FDA-approved patient medication guide, which is available with the product information and at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125370s055lbl.pdf#page=21, must be dispensed with this medication.
Monitor for hypersensitivity reactions; onset may occur within hours of the infusion or may be delayed. Non-acute hypersensitivity reactions, including facial edema, fatigue, headache, myalgia, nausea, and rash have been reported and may occur up to a week following infusion. Immediately discontinue infusion for severe reactions and contact provider.

Medications
☐ Belimumab (benlysta) Autoinjector Or Prefilled Syringe

Belimumab (BENLYSTA) prefilled autoinjector 200 mg
200 mg, Subcutaneous, Once, Starting S, For 1 Dose
Allow prefilled syringe and autoinjector to warm to room temperature for 30 minutes prior to administration; do not warm product in any other way. Administer SubQ using a different injection site on the same day each week; do not administer into tender, bruised, red, or hard skin. Initial use is recommended under supervision of physician; self-injection may occur after proper training.

Belimumab (BENLYSTA) prefilled syringe 200 mg
200 mg, Subcutaneous, Once, Starting S, For 1 Dose
Allow prefilled syringe and autoinjector to warm to room temperature for 30 minutes prior to administration; do not warm product in any other way. Administer SubQ using a different injection site on the same day each week; do not administer into tender, bruised, red, or hard skin. Initial use is recommended under supervision of physician; self-injection may occur after proper training.

Telephone order/Verbal order documented and read-back completed. Practitioner’s initials ____________

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

EPIC VERSION DATE:
X25260 (5/21) – Page 1 of 1 © Spectrum Health

NOTE: Epic Treatment/Therapy Plan Orders. To be scanned/attached to the appropriate Infusion Referral Order in Epic.